Greenwich LifeSciences, Inc.

NASDAQ:GLSI

Biotechnology

Healthcare
$20.58 -3.08%

-$0.74 today

Market cap
$302.08M
Beta
1.38
P/E (TTM)
-15.6
EPS (TTM)
-$1.49
52W Low $7.78High $34.10

Volume 0.71M

Average 0.14M

GLSI Total Current Liabilities

All obligations due within one year.

Greenwich LifeSciences, Inc.NASDAQ: GLSI

Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Total current liabilities rises 263.9% from a year ago

Total current liabilities stood at $5.24M at the end of Q1 FY2026, up 263.9% from a year earlier and down 10.1% from the prior quarter. Over 3 fiscal years it compounded at +180.9% a year.

Context

  • Total current liabilities amounted to 49.8% of total assets at the end of Q1 FY2026, down 2.5 pp from a year earlier.
  • Total current liabilities increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total current liabilities keeps rising in the next quarterly balance sheet after a +263.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.24M-10.1% QoQ
Last fiscal yearDec 2025
$5.82M+273.4% YoY
Year agoMar 2025
$1.44M+263.9% since
Total Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+263.9%——
1 year+273.4%——
3-year CAGR+180.9%——
5-year CAGR——
10-year CAGR——

Total Current Liabilities history

USD · from the balance sheet

Latest · FY2025
5.82M USD
Year-over-year change
+273.4%
4-year CAGR
+97.2%

Total Current Liabilities vs competitors

How GLSI compares with its peers on the latest reported figures

  • Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +263.9% is the highest of 9, against a peer median of -7.8%.
  • Total current liabilities amounts to 49.8% of total assets for GLSI, versus a peer median of 15.4%.
GLSI Competitors
Total Current Liabilities for GLSI and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AGENAgenus Inc.Mar 2026$249.24M USD+19.7%+19.6%133.7%
IMMXImmix Biopharma, Inc.Mar 2026$10.54M USD+13.2%+99.5%11.0%
SEERSeer, Inc.Mar 2026$10.24M USD-22.4%+7.6%3.8%
SRZNSurrozen, Inc.Mar 2026$9.57M USD-9.6%+0.7%7.9%
IRDOpus Genetics, Inc.Mar 2026$9.34M USD-61.5%+41.4%14.0%
HURATuHURA Biosciences, Inc.Mar 2026$6.07M USD+26.9%+27.3%20.4%
CGTXCognition Therapeutics, Inc.Mar 2026$6.05M USD-44.7%+21.3%16.7%
ONCYOncolytics Biotech Inc.Mar 2026CA$5.42M CAD-6.0%+28.5%66.5%
GLSIGreenwich LifeSciences, Inc.Mar 2026$5.24M USD+263.9%+180.9%49.8%
Peer median (excluding GLSI) —-7.8%+24.3%15.4%

Competitors are the stored peer set for GLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents27.2M13.47M6.99M4.09M(6.74M)
Short-term Investments00000
Net Receivables00000
Inventory00000
Other Current Assets00000
Total Current Assets27.2M13.47M6.99M4.09M(6.74M)
Property, Plant & Equipment (Net)00000
Goodwill00000
Intangible Assets12.62K9K5.39K1.78K0
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00000
Total Non-current Assets12.62K9K5.39K1.78K0
Total Assets27.22M13.48M6.99M4.09M(6.74M)
Account Payables0035.47K1.18M0
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities000382.2K5.55M
Total Current Liabilities385.17K262.91K294.41K1.56M5.82M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities00000
Total Liabilities385.17K262.91K294.41K1.56M2.02M
Common Stock13.15K12.85K12.85K13.15K14.3K
Retained Earnings(33.65M)(41.47M)(50.36M)(66.15M)(87.14M)
Accumulated OCI(0)0000
Other Stockholders Equity00001.79M
Minority Interest00000
Total Equity26.83M13.21M6.7M2.53M1.79M
Total Debt00000
Net Debt(27.2M)(13.47M)(6.99M)(4.09M)6.74M

Greenwich LifeSciences, Inc.

NASDAQ:GLSI

Intrinsic Alpha fair value

Locked

Current Price

$20.58

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.